Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line

Investigational New Drugs

Volumn 31, Issue 5, 2013, Pages 1158-1168

  Funakoshi, Yohei ^a   Mukohara, Toru ^a   Tomioka, Hideo ^a   Ekyalongo, Roudy Chiminch ^a   Kataoka, Yu ^a   Inui, Yumiko ^a   Kawamori, Yuriko ^a   Toyoda, Masanori ^a   Kiyota, Naomi ^a   Fujiwara, Yutaka ^a,b   Minami, Hironobu ^a  

^a KOBE UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acquired resistance; Addiction; Gastric cancer; MET inhibitor

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ATR PROTEIN; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; FORETINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; G1 PHASE CELL CYCLE CHECKPOINT; GENE DOSAGE; GENE EXPRESSION; MET GENE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; SULFONES;

EID: 84884813101     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9959-2     Document Type: Article

References (34)

1. Vlahovic G, Crawford J (2003) Activation of tyrosine kinases in cancer. Oncologist 8(6):531-538
2. Weinstein IB (2002) Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297(5578):63-64. doi: 10.1126/science.1073096
3. Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68(9):3077-3080. doi: 10.1158/0008-5472.CAN-07-3293, discussion 3080
4. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733-2743. doi: 10.1056/NEJMoa064320
5. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380-2388. doi: 10.1056/NEJMoa0909530
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123-132. doi: 10.1056/NEJMoa050753
7. Sierra JR, Tsao MS (2011) c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 3(1 Suppl):S21-S35. doi: 10.1177/1758834011422557
8. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104(52):20932-20937. doi: 10.1073/pnas.0710370104
9. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039-1043. doi: 10.1126/science.1141478
10. McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J (2010) Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 70(4):1625-1634. doi: 10.1158/0008-5472.CAN-09-3620
11. Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, Comoglio PM, Giordano S (2010) MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 70(19):7580-7590. doi: 10.1158/0008-5472.CAN-10-0436
12. Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Janne PA, Engelman JA (2011) Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 71(3):1081-1091. doi: 10.1158/0008-5472.CAN-10-1623
13. Rege-Cambrin G, Scaravaglio P, Carozzi F, Giordano S, Ponzetto C, Comoglio PM, Saglio G (1992) Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. Cancer Genet Cytogenet 64(2):170-173
14. Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Janne PA (2005) Inhibition of the met receptor in mesothelioma. Clin Cancer Res 11(22):8122-8130. doi: 10.1158/1078-0432.CCR-05-1191
15. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T (2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12(19):5764-5769. doi: 10.1158/1078-0432.CCR-06-0714
16. Engelman JA, Settleman J (2008) Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 18(1):73-79. doi: 10.1016/j.gde.2008.01.004
17. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol Off J Am Soc Clin Oncol 24(29):4764-4774. doi: 10.1200/JCO.2006.06.2265
18. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2):117-125
19. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Janne PA (2006) Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-Amplified lung cancer. J Clin Invest 116(10):2695-2706. doi: 10.1172/JCI28656
20. Suda K, Tomizawa K, Osada H, Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T (2012) Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer 76(3):292-299. doi: 10.1016/j.lungcan. 2011.11.007
21. Tsantoulis PK, Kotsinas A, Sfikakis PP, Evangelou K, Sideridou M, Levy B, Mo L, Kittas C, Wu XR, Papavassiliou AG, Gorgoulis VG (2008) Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study. Oncogene 27(23):3256-3264. doi: 10.1038/sj.onc.1210989
22. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434(7035):907-913. doi: 10.1038/nature03485
23. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434(7035):864-870. doi: 10.1038/nature03482
24. Fridman JS, Lowe SW (2003) Control of apoptosis by p53. Oncogene 22(56):9030-9040. doi: 10.1038/sj.onc.1207116
25. Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ (2002) Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 22(6):1834-1843
26. Lu X, Nannenga B, Donehower LA (2005) PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 19(10):1162-1174. doi: 10.1101/gad.1291305
27. Myers K, Gagou ME, Zuazua-Villar P, Rodriguez R, Meuth M (2009) ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress. PLoS Genet 5(1):e1000324. doi: 10.1371/journal.pgen.1000324
28. Shenberger JS, Dixon PS (1999) Oxygen induces S-phase growth arrest and increases p53 and p21(WAF1/CIP1) expression in human bronchial smooth-muscle cells. Am J Respir Cell Mol Biol 21(3):395-402
29. Yao J, Duan L, Fan M, Yuan J, Wu X (2007) Overexpression of BLCAP induces S phase arrest and apoptosis independent of p53 and NF-kappaB in human tongue carcinoma: BLCAP overexpression induces S phase arrest and apoptosis. Mol Cell Biochem 297(1-2):81-92. doi: 10.1007/s11010-006-9332-2
30. Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol Off J Am Soc Clin Oncol 25(9):1107-1113. doi: 10.1200/JCO.2006.09.0183
31. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH, Miller VA (2007) Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13(17):5150-5155. doi: 10.1158/1078-0432.CCR-07-0560
32. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol Off J Am Soc Clin Oncol 26(4):626-632. doi: 10.1200/JCO.2007.13.4452
33. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41(12):1751-1757. doi: 10.1016/j.ejca.2005.04.034
34. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL (2008) Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14(6):485-493. doi: 10.1016/j.ccr.2008.11.001